How to Help Your Patients Find Ticagrelor in Stock: A Provider's Guide

Your Patient Can't Find Ticagrelor — Here's How to Help

You've prescribed Ticagrelor for good clinical reasons. Your patient needs dual antiplatelet therapy to prevent a recurrent MI, manage their ACS, or reduce stroke risk. But they call your office saying their pharmacy doesn't have it in stock.

This scenario is more common than it should be, and it puts patients at real risk of treatment gaps. As a provider, you're in a unique position to help — and a few simple workflow adjustments can make a big difference in your patients' ability to access this critical medication.

Current Ticagrelor Availability

As of early 2026, Ticagrelor is not in a national shortage. Generic ticagrelor has been available since 2023, with multiple manufacturers now producing both the 60 mg and 90 mg tablet strengths. Overall national supply is adequate.

However, patients frequently encounter localized stock-outs — situations where their specific pharmacy doesn't carry ticagrelor or has temporarily run out. This is particularly common at:

• Chain pharmacies in areas with lower cardiovascular patient volumes
• Pharmacies transitioning their inventory from brand Brilinta to generic
• Locations where wholesaler contracts have changed

For the latest supply data and shortage tracking, see our provider shortage briefing for 2026.

Why Patients Can't Find Ticagrelor

Understanding the root causes helps you advise patients more effectively:

Automated Inventory Management

Most chain pharmacies use just-in-time inventory systems that order medications based on recent dispensing data. A pharmacy that rarely fills ticagrelor may not stock it at all, creating a catch-22: they don't order it because they don't dispense it, and they don't dispense it because they don't have it.

Formulary and Payer Dynamics

Some insurance plans prefer clopidogrel as first-line antiplatelet therapy and require prior authorization or step therapy for ticagrelor. Pharmacies stocking decisions often follow payer formularies, so if most patients at a given location are on plans that prefer clopidogrel, the pharmacy may not carry ticagrelor.

Cost Confusion

When patients see a retail price of $444 for generic ticagrelor, some abandon the prescription at the counter — not realizing that a free discount card could reduce their cost to as low as $31. This abandonment further reduces dispensing volume, which further reduces pharmacy stocking.

What Providers Can Do: 5 Practical Steps

Step 1: Prescribe Generic Ticagrelor by Default

Ensure your e-prescribing templates default to generic ticagrelor rather than brand Brilinta. This avoids DAW-related substitution issues and ensures patients get the most affordable option. Generic ticagrelor is AB-rated and therapeutically equivalent to Brilinta.

Step 2: Use Medfinder to Verify Stock Before Prescribing

Medfinder for providers allows your clinical staff to check real-time pharmacy inventory before sending a prescription. This takes less than a minute and can prevent the frustrating experience of a patient driving to a pharmacy only to be told the medication isn't available.

Consider adding a Medfinder stock check to your prescribing workflow for ticagrelor and other medications that patients commonly report difficulty finding.

Step 3: Recommend Independent Pharmacies

When patients report stock-outs at chain pharmacies, recommend they try an independent or specialty pharmacy. Independent pharmacies typically:

• Have more flexible ordering relationships with multiple wholesalers
• Can special-order medications within 1-2 business days
• Provide more personalized service and follow-up
• Are often willing to price-match or accept discount cards

Step 4: Proactively Discuss Cost and Savings Options

Many patients don't fill prescriptions because of cost concerns — and they may not tell you. Take 30 seconds during the prescribing conversation to mention:

• Generic ticagrelor is available and much cheaper than brand Brilinta
• Free discount cards (like SingleCare) can reduce the cost to around $31/month
• AstraZeneca's AZ&Me program provides free Brilinta to qualifying patients
• The Brilinta Savings Card can reduce commercially insured copays to as low as $18/month

For a comprehensive patient-facing resource, direct patients to our guide on how to save money on Ticagrelor.

Step 5: Have a Bridging Strategy Ready

For patients who truly cannot locate ticagrelor, have a bridging plan prepared:

• Office samples: Keep ticagrelor samples on hand if available from your AstraZeneca representative
• Short-term clopidogrel: Prescribe clopidogrel 75 mg daily as a temporary bridge while the patient locates ticagrelor. Document the clinical rationale and plan to switch back.
• Prescription transfer: Help the patient transfer their prescription to a pharmacy that has ticagrelor in stock (use Medfinder to identify one)

Alternative Agents to Consider

If ticagrelor is unavailable or if clinical circumstances warrant a change, the main alternatives are:

• Clopidogrel (Plavix): Widely available, very affordable (often under $10/month generic). Consider CYP2C19 testing for patients where clopidogrel efficacy is critical. Not as potent as ticagrelor in ACS per PLATO trial data.
• Prasugrel (Effient): More potent platelet inhibition than clopidogrel. Generic available at $15-$50/month. Contraindicated in prior stroke/TIA. Higher bleeding risk in elderly and low-weight patients.
• Cangrelor (Kengreal): IV option for periprocedural use when oral P2Y12 inhibitors are not an option.

For a patient-appropriate comparison, direct patients to our post on alternatives to Ticagrelor.

Workflow Tips for Your Practice

• Flag ticagrelor patients: Consider a registry or EHR flag for patients on ticagrelor so you can proactively address refill issues at follow-up visits
• Coordinate with pharmacy: For patients starting ticagrelor, have staff confirm the dispensing pharmacy has stock before the patient leaves
• Provide written cost information: Include discount card information in your after-visit summary so patients have it at the pharmacy counter
• Document aspirin dose: Include specific aspirin dosing (75-100 mg/day maintenance) in the patient's medication list and discharge/visit instructions to prevent inadvertent high-dose aspirin use, which reduces ticagrelor effectiveness per the boxed warning
• Educate on adherence: Emphasize that stopping ticagrelor abruptly — especially with a coronary stent — carries significant thrombotic risk. Patients need to understand this isn't a medication they can skip.

Final Thoughts

Ticagrelor access issues are usually solvable with the right approach. By integrating stock verification, cost counseling, and bridging strategies into your prescribing workflow, you can significantly reduce the risk of treatment gaps for your patients.

Medfinder for providers is a free tool designed to help your practice navigate medication availability challenges. For more resources, see our Ticagrelor shortage briefing for 2026 and our guide to helping patients save money on Ticagrelor.